Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Case Study: Eisai Partners With Swedish Startup BioArctic In Search Of Cure For Alzheimer’s Disease (Part 2 Of 2)

This article was originally published in PharmAsia News

Executive Summary

Eisai has taken an aggressive approach in seeking out the right partners to fill out its pipelines. The company's partnership with Swedish startup BioArctic to develop a drug for Alzheimer's disease is no exception. Eisai and BioArctic discussed the beginnings of their partnership in the first part of this case study (PharmAsia News, Aug. 6, 2008). This second section discusses in greater detail why the companies view the partnership as a success and what each has brought to the other.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts